Characteristics | Survivor (n = 86) | Non-survivor (n = 15) | p-value |
---|---|---|---|
Age in years, median (IQR) | 55 (45–63) | 61(51–67) | 0.115 |
Male, n (%) | 62 (61) | 15 (39) | 0.019 |
BMI, kg/m2, median (IQR) | 28 (25–32) | 28 (26–31) | 0.586 |
Days of symptoms upon admission, median (IQR) | 8 (6–10) | 8 (7–10) | 0.920 |
APACHE II, median (IQR) | 8 (7–10) | 11 (8–13) | 0.035 |
SOFA, median (IQR) | 4 (3–4) | 5 (4–5) | < 0.001 |
NEWS II, median (IQR) | 11 (9–13) | 11 (10–13) | 0.110 |
LUS at admission, points, median (IQR) | 21 (19–25) | 26 (25–27) | < 0.001 |
PaO2/FiO2 ratio (mmHg), at admission, median (IQR) | 106 (95–137) | 95 (79–105) | 0.012 |
Comorbidities | |||
Diabetes, n (%) | 5 (5) | 0 (0) | 1.000 |
Hypertension, n (%) | 10 (9) | 2 (1) | 0.851 |
Asthma, n (%) | 2 (2) | 0 (0) | 1.000 |
COPD, n (%) | 1 (1) | 0 (0) | 1.000 |
Congestive heart failure, n (%) | 3 (3) | 2 (1) | 0.158 |
Non-Invasive Respiratory Support | |||
High-Flow Nasal Cannula, n (%) | 57 (66) | 4 (26) | N/A |
Switched to CPAP, n (%) | 29 (33) | 11 (73) | N/A |
ROXi at 2-h, median (IQR) | 8.04 (7.52–10.35) | 8.03 (5.62–10.14) | 0.538 |
ROXi at 6-h, median (IQR) | 8.90 (7.08–10.66) | 9.12 (6.60–10.70) | 0.789 |
ROXi at 12-h, median (IQR) | 9.30 (7.62–11.35) | 7.75 (6.12-10.00) | 0.029 |
ROXi at 24-h, median (IQR) | 10.26 (8.17–14.29) | 6.96 (5.78-9.00) | < 0.001 |
ROXi at 48-h, median (IQR) | 10.26 (8.17–14.29) | 4.43 (3.70–5.55) | < 0.001 |
Laboratory test | |||
D-Dimer, (µg/L), median (IQR) | 348 (259–650) | 390 (315–587) | 0.497 |
C-Reactive Protein, (mg/L), median (IQR) | 11 (6–15) | 9 (6–19) | 0.882 |
Ferritin, (µg/L), median (IQR) | 819 (455–1363) | 1182 (745–1500) | 0.231 |
pH, median (IQR) | 7.41 (7.40–7.44) | 7,42 (7.41–7.43) | 0.604 |
PaCO2 mmHg, median (IQR) | 35 (32–37) | 35 (34–38) | 0.591 |
PaO2, mmHg, median (IQR) | 85 (76–107) | 72 (62–84) | 0.014 |
HCO3 meq/l, median (IQR) | 22 (21–24) | 23 (21–24) | 0.837 |